Irritable bowel syndrome is rarely serious, but is still an inconvenience and a painful disorder for patients who have it. For patients who have IBS or are concerned they may have it, how can you explain the basics of how it is detected and managed?
Results showed that the majority of patients expressed dissatisfaction with the effect of the OTC agent on constipation and CIC-specific abdominal symptoms.
Researchers conducted a double-blind study to assess the effect of naldemedine therapy vs placebo in reducing symptoms associated with opioid-induced constipation.
Each DocuSol Kids mini-enema (5mL) contains a delivered dose of docusate sodium 100mg in a polyethylene glycol base.
Conventional approaches to treatment of opioid-induced constipation include the use of treatment modalities that address non-opioid-related constipation as well as new medications that target the OIC mechanism of action.
The recommendations have been published in the AGA’s official journal, Gastroenterology.
While several secretagogues have been recently approved by the Food and Drug Administration (FDA), a lack of head-to-head trials led researchers to conduct a systematic review to compare the effectiveness of these agents in patients with IBS-C.
Strong evidence for efficacy has been established for stimulant and osmotic laxatives, new intestinal secretagogues, and peripherally restricted μ-opiate receptor antagonists, according to a review in JAMA.
